Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
UCB (company)

UCB (company)

A biopharmaceutical company focusing on discovery and development of treatments for neurology and immunology conditions

UCB is a biopharmaceutical company that focuses on creating value for people who are living with severe diseases in immunology and neurology now and in the future.

The company works with stakeholders to address unmet needs of patients and caregivers, helping them to attain their goals and live the lives they want.

UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives, while creating value for society. The company's commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how that are required to serve patients in need.

UCB focuses on neurology and immunology disorders by putting patients at the center of its world. UCB is continuously working to advance science and embrace new knowledge and it is leveraging scientific advances and skills in areas such as genetics, biomarkers and human biology.

Scientists at UCB collaborate with leading researchers from the industry and academia to advance science and offer the solutions that patients need.

Timeline

Patents

Further Resources

Title
Author
Link
Type
Date

Clinical studies at UCB: How are medicines made and tested?

Web

September 23, 2019

Métier Biotech Manufacturing

Web

November 17, 2021

News

Search on Google
Search on Bing
Title
Author
Date
Publisher
Description
August 23, 2021
Moneycontrol
The expert committee on Urban Co-operative Banks (UCBs) has submitted its report in two parts, a vision document for the UCB sector and the second part is on the committee's recommendations on various aspects of the functioning of UCBs.
Veeva Systems
June 1, 2021
www.prnewswire.com:443
/PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that leaders from Boehringer Ingelheim, GSK, and UCB will be among the featured keynote speakers at...
Veeva Systems
June 1, 2021
www.prnewswire.com:443
/PRNewswire/ -- Veeva Systems (NYSE: VEEV) hat heute bekannt gegeben, dass Führungskräfte von Boehringer Ingelheim, GSK und UCB zu den Hauptrednern auf dem...
BioSpace
May 25, 2021
BioSpace
Iktos, a company specialized in Artificial Intelligence for new drug design and UCB, a global biopharma company focusing on neurology and immunology, today announced a software licensing agreement related to AI-based retrosynthesis analysis and planning tool SpayaTM which will be used to empower synthetic and medicinal chemistry projects for drug design and discovery of new chemical entities within UCB.
BioSpace
May 17, 2021
BioSpace
Neuropore Therapies, Inc. announced today that it has earned a milestone payment related to its collaboration with UCB and the evaluation of UCB0599 for the treatment of Parkinson's Disease. UCB0599 is an orally administered small molecule alpha-synuclein misfolding inhibitor arising from a Collaboration and License Agreement entered into between Neuropore Therapies, Inc and UCB Biopharma SRL on December 31, 2014.
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.